Sales of analgesics are set to enjoy appreciable progression in 2022, following an already surprisingly robust performance at the end of 2021. Most players anticipated a strong comeback from typical pre-pandemic ailments in 2022. Nonetheless, it came sooner than anticipated. The COVID-19 vaccination campaign in Belgium was fairly successful. By September 2021, over 70% of Belgians had already received two booster doses, with the country looking to achieve collective immunity in advance of the co...
Euromonitor International's Analgesics in Belgium report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.
Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market's major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Analgesics in Belgium
Euromonitor International
September 2022
List Of Contents And Tables
ANALGESICS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
The return of "normal" pathologies comes sooner than anticipated
Topical analgesics/anaesthetic back in business too
Dafalgan and generics benefit from the ongoing breakthrough of acetaminophen
PROSPECTS AND OPPORTUNITIES
Normalisation and thus maturity expected over 2023-2027
Possible risks of shortage, mainly in generics
Other disparate effects
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2017-2022
Table 2 Sales of Analgesics by Category: % Value Growth 2017-2022
Table 3 NBO Company Shares of Analgesics: % Value 2018-2022
Table 4 LBN Brand Shares of Analgesics: % Value 2019-2022
Table 5 Forecast Sales of Analgesics by Category: Value 2022-2027
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2022-2027
CONSUMER HEALTH IN BELGIUM
EXECUTIVE SUMMARY
Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 8 Life Expectancy at Birth 2017-2022
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2017-2022
Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
Table 15 Distribution of Consumer Health by Format and Category: % Value 2022
Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources